Latest Conference Articles

Experts preview key bladder, kidney, and prostate cancer trials to watch at the 2026 Genitourinary Cancers Symposium.

At the OncLive National Fellows Forum during SABCS 2025, notable data were presented on ethnic differences in early HR+ breast cancer and genomic insights in women post partum.

Bladder cancer experts share the most anticipated abstracts expected at the 2026 Genitourinary Cancers Symposium.

OncLive heard from experts across oncology specialties about the biggest updates from the 2026 Transplantation and Cellular Therapy Meetings.

Experts preview key prostate cancer abstracts to watch at the 2026 Genitourinary Cancers Symposium.

Experts highlight key RCC studies at the 2026 Genitourinary Cancers Symposium, with a focus on combination-based strategies and patient-reported outcomes.

Age was correlated with worse survival among those undergoing allogenic hematopoietic cell transplantation for acute lymphoblastic leukemia.

Nathan Denlinger, DO, discusses real-world data with second-line liso-cel and axi-cel in patients with relapsed/refractory large B-cell lymphoma.

Fernando Gibran-Nunes, MD, highlights findings from a meta-analysis investigating the efficacy and safety of loncastuximab tesirine in pretreated DLBCL.

CARTITUDE-4 data show heterogeneous outcomes with cilta-cel after progression on bridging therapy in relapsed/refractory multiple myeloma.

Peter Riedell, MD, discussed the long-term efficacy of tisagenlecleucel in the third-line setting in patients with relapsed/refractory follicular lymphoma.

Kenneth Jin Chang Lim, MBBS, discusses the failure of dexamethasone to reduce rates of neurotoxicity in myeloma with high ALC after CAR T-cell therapy.

Real-world data show over an 40% response rate for lifileucel TIL therapy, for previously treated advanced melanoma.

Only a proportion of patients with advanced melanoma proceeded to TIL therapy following referral in a real-world setting.

Cilta-cel was linked with low progression events and a potential cure fraction in relapsed/refractory multiple myeloma.

Adoptive cell therapy elicited MRD-negative responses with low rates of GVHD and neurotoxicities in adult patients with high-risk B-ALL.

A real-world cilta-cel study revealed a link between high lymphocyte peaks and failed bridging to parkinsonism and nonrelapse mortality, potentially guiding early intervention.

Orca-T/reduced-intensity conditioning was effective and decreased GVHD incidence vs PTCy/reduced-intensity conditioning in hematologic malignancies.

Real-world data confirm the importance of tumor debulking with bridging therapy to reduce the risk of parkinsonism and NRM with cilta-cel in myeloma.

Ustekinumab plus prophylaxis did not reduce acute GVHD in patients who underwent HCT from matched unrelated donors.

No serious adverse effects were observed with TRX103 in patients with hematologic malignancies undergoing HLA-mismatched HCT.

Prophylactic dexamethasone did not reduce the risk of developing DNT, nor the severity of DNT presentation, in cilta cel–treated myeloma with high ALC.

Acalabrutinib yielded durable organ-specific responses and a manageable safety profile in patients with steroid-refractory chronic graft-vs-host disease.

Ahead of the 2026 Transplantation & Cellular Therapy Meetings, experts preview data on CAR T-cell therapy efficacy, donor access, and toxicity mitigation.

Experts reflect on pivotal data from the 2026 Gastrointestinal Cancers Symposium that are set to change practice in HCC, CRC, and other GI cancers.

The addition of mFOLFOX6 and bevacizumab to atezolizumab improved PFS compared with atezolizumab monotherapy in dMMR/MSI-H mCRC.

Encorafenib plus cetuximab and FOLFIRI significantly improved response vs standard therapy in first-line BRAF V600E–mutant metastatic colorectal cancer.

Penipulimab plus anlotinib and chemotherapy showed improved efficacy compared with chemotherapy alone in treatment-naïve metastatic pancreatic cancer.

Nivolumab plus ipilimumab continued to yield an efficacy and safety benefit vs lenvatinib or sorafenib in previously untreated, unresectable HCC.

Atezolizumab plus bevacizumab could yield superior outcomes compared with TACE in intermediate-stage HCC.